Ogihara-Umeda I, Sasaki T, Kojima S, Nishigori H
Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan.
J Nucl Med. 1996 Feb;37(2):326-32.
We conducted a systematic study of the effects of liposome formulation and encapsulated radionuclides on imaging ability.
Various types of liposomes were prepared and labeled with 67Ga, 111In or 99mTc. Their tumor-imaging potential was evaluated in terms of tumor accumulation and tumor-to-blood ratios of radioactivity delivered by the liposomes. Mouse sarcoma 180 and Ehrlich solid tumor were the tumor models.
Liposomes could be labeled rapidly and with high efficiency, which was sufficient for clinical application. Tumor accumulation of liposome-encapsulated radionuclides that have intrinsic tumor affinity, such as 67Ga-NTA or 111In-NTA, was larger than that of the other nuclides. Liposomes that were fairly small, cholesterol-rich and composed of so-called rigid phospholipids, could deliver large amounts of encapsulated radionuclides to the tumor. We also found that tumor uptake of such liposomes was large and their blood retention was prolonged. Liposomal lipid dose also influenced tumor delivery and blood retention. The results suggest that these factors extended liposomal blood retention and, consequently, increased tumor uptake of the liposomes and tumor delivery of encapsulated radionuclides. Not all liposomes with long blood retention, however, are suitable for tumor imaging. Incorporation of monosialo-ganglioside in the liposomal membrane greatly extended blood retention but increased tumor uptake only slightly and, consequently, made the tumor-to-blood value worse. One of the 67Ga-labeled liposome formulations resulted in high tumor uptake and tumor-to-blood ratios in various tumor models as well as clearly visualized tumors clearly in sarcoma 180-bearing mice.
For tumor imaging with radiolabeled liposomes, we should choose liposomal formulations and dose to give prolonged blood retention for large tumor delivery. We must then select liposomes that give good tumor-to-blood values. For the best results, the radionuclide should have intrinsic tumor affinity. Labeled liposomes that meet these criteria result in excellent tumor images.
我们对脂质体制剂和包封的放射性核素对成像能力的影响进行了系统研究。
制备了各种类型的脂质体,并用67Ga、111In或99mTc进行标记。根据脂质体递送的放射性的肿瘤蓄积和肿瘤与血液的比率评估它们的肿瘤成像潜力。小鼠肉瘤180和艾氏实体瘤为肿瘤模型。
脂质体能够快速且高效地进行标记,这足以用于临床应用。具有内在肿瘤亲和力的包封放射性核素的脂质体,如67Ga-NTA或111In-NTA,其肿瘤蓄积大于其他核素。相当小、富含胆固醇且由所谓刚性磷脂组成的脂质体能够将大量包封的放射性核素递送至肿瘤。我们还发现,此类脂质体的肿瘤摄取量大且其在血液中的滞留时间延长。脂质体脂质剂量也影响肿瘤递送和血液滞留。结果表明,这些因素延长了脂质体在血液中的滞留时间,从而增加了脂质体的肿瘤摄取以及包封放射性核素的肿瘤递送。然而,并非所有血液滞留时间长的脂质体都适用于肿瘤成像。在脂质体膜中掺入单唾液酸神经节苷脂极大地延长了血液滞留时间,但仅略微增加了肿瘤摄取,因此使肿瘤与血液的值变差。一种67Ga标记的脂质体制剂在各种肿瘤模型中导致高肿瘤摄取和肿瘤与血液的比率,并且在荷肉瘤180小鼠中清晰地显示出肿瘤。
对于用放射性标记脂质体进行肿瘤成像,我们应选择能延长血液滞留时间以实现大量肿瘤递送的脂质体制剂和剂量。然后我们必须选择具有良好肿瘤与血液值的脂质体。为获得最佳结果,放射性核素应具有内在肿瘤亲和力。符合这些标准的标记脂质体可产生出色的肿瘤图像。